On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

NEW YORK – Singapore's Experimental Drug Development Center (EDCC) will use Engine Biosciences' machine learning platform to advance precision cancer therapies, according to a partnership announced ...

In a mouse model, a single dose of ATL-201 durably suppressed seizures and improved behavior through six months, according to the firm.

NEW YORK – Adaptin Bio on Monday said it has completed a reverse merger with a subsidiary of Unite Acquisition 1 Corp to bring the company public and closed a private placement worth up to $7.7 ...

The new approval makes the regimen an option for around 4,000 patients in the EU who have at least one non-class I CFTR mutation.

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

The firm plans to use improvement in left ventricular mass index and increased frataxin protein expression after LX2006 treatment as co-primary endpoints.

The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...